Uneasy feeling for US industry as detail emerges of 510(k) overhaul
This article was originally published in RAJ Devices
Executive Summary
"These two preliminary reports recommend steps to strengthen and improve the 510(k) process and the use of science in decision making" and provide a "blueprint for smarter medical device oversight". That is the understated way in which Jeffrey Shuren, director of the US Food and Drug Administration's Center for Devices and Radiological Health, described what are likely to be the biggest changes to the regulation of low- to medium-risk medical devices for 34 years1.
You may also be interested in...
Report Digest: Discussing What's Going On With Prostate Cancer Diagnosis And Treatment
In this edition of Report Digest, UK-based reporter Barnaby Pickering talks about the prostate cancer diagnostics and minimally invasive treatments markets with analyst Phil Greenfield. The two discuss ongoing developments in both treatment and diagnosis, while exploring driving and limiting factors for both.
Using Digital Tools To Unpick The Adherence Problem
An ambitious five-year public-private partnership plans to tackle non-adherence to medicines by giving patients EU-wide access to regulator-approved digital drug information. One year in, progress has been made in creating an app that could do just this.
In A First, FDA Approves Radioembolization Treatment For Liver Cancer In US
Approval for Boston Scientific’s TheraSphere offers further access to the therapy that, until now, has only been available under a humanitarian device exemption.